score_bin	sensitive_predictive_implication	resistance_predictive_implication	prognostic_predictive_implication	feature_type	feature	alteration_type	alteration	tumor_f	total_coverage	exac_af	exac_common	clinvar	sensitive_score_bin	sensitive_therapy_name	sensitive_therapy_strategy	sensitive_therapy_type	sensitive_description	sensitive_citation	sensitive_url	resistance_score_bin	resistance_therapy_name	resistance_therapy_strategy	resistance_therapy_type	resistance_description	resistance_citation	resistance_url	prognostic_score_bin	favorable_prognosis	prognostic_description	prognostic_citation	prognostic_url	number_germline_mutations_in_gene	validation_total_coverage	validation_tumor_f	validation_detection_power	feature_display	preclinical_efficacy_observed	patient_id	tumor_sample_barcode	normal_sample_barcode
Putatively Actionable	Clinical evidence		Guideline	Somatic Variant	NRAS	Missense	p.Q61L	0.6401	1592.0	0.0	0.0		Putatively Actionable	Selumetinib	MEK inhibition	Targeted therapy	Presence of this variant may suggest sensitivity to Selumetinib.	Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol. 2008;26(13):2139-46.	https://doi.org/10.1200/JCO.2007.14.4956								Investigate Actionability	0.0	More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	493.0	0.7201	1.0	NRAS p.Q61L (Missense)	1.0	MEL-IPI_Pat19	MEL-IPI_Pat19-Tumor-SM-4DK1F	MEL-IPI_Pat19-Normal-SM-4NFUL
Investigate Actionability	Clinical evidence			Mutational Burden	High Mutational Burden								Investigate Actionability	Ipilimumab	CTLA-4 inhibition	Immunotherapy	In a study of malignant melanoma using a discovery cohort of 25 patients and a validation cohort of 39 patients, a significantly higher muational burden was seen in patients with a long-term clinical benefit vs. patients with minimal or no benefit to ipilimumab treatment.	Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014;371(23):2189-99.	https://doi.org/10.1056/NEJMoa1406498													0				 mutations per Mb		MEL-IPI_Pat19		
Investigate Actionability			Guideline	Somatic Variant	SETBP1	Missense	p.D1389N	0.1955	133.0	0.0	0.0																Investigate Actionability	0.0	Associated with disease progression. More frequent in Chronic Myelomonocytic Leukemia and Juvenile Myelomonocytic Leukemia.	National Comprehensive Cancer Network. Myelodysplastic Syndromes NCCN Evidence Blocks (Version 1.2017). https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf. Accessed November 5, 2016.	https://www.nccn.org/professionals/physician_gls/pdf/mds_blocks.pdf	0	22.0	0.0909	0.6508	SETBP1 p.D1389N (Missense)		MEL-IPI_Pat19	MEL-IPI_Pat19-Tumor-SM-4DK1F	MEL-IPI_Pat19-Normal-SM-4NFUL
Investigate Actionability			Inferential	Aneuploidy	Whole genome doubling																						Investigate Actionability	0.0	WGD was associated with adverse survival pan-cancer in patients with advanced disease and in cancers with heterogeneous clinical outcomes, even following the development of metastasis.	Bielski CM, Zehir A, Penson AV, et al. Genome doubling shapes the evolution and prognosis of advanced cancers Nat Genet. 2018; 50(8):1189-1195.	https://doi.org/10.1038/s41588-018-0165-1	0						MEL-IPI_Pat19		
Biologically Relevant				Somatic Variant	COL1A1	Splice Site	p.K1033K	0.1579	171.0	0.0	0.0																					0	7793.0	0.0	1.0	COL1A1 p.K1033K (Splice Site)		MEL-IPI_Pat19	MEL-IPI_Pat19-Tumor-SM-4DK1F	MEL-IPI_Pat19-Normal-SM-4NFUL
Biologically Relevant				Somatic Variant	COL1A1	Missense	p.P535L	0.406	234.0	0.0	0.0																					0	8800.0	0.0049	1.0	COL1A1 p.P535L (Missense)		MEL-IPI_Pat19	MEL-IPI_Pat19-Tumor-SM-4DK1F	MEL-IPI_Pat19-Normal-SM-4NFUL
Biologically Relevant				Copy Number	NRAS	Amplification				0.0	0.0																					0				NRAS Amplification		MEL-IPI_Pat19	MEL-IPI_Pat19-Tumor-SM-4DK1F	
Biologically Relevant				Copy Number	GATA3	Deletion				0.0	0.0																					0				GATA3 Deletion		MEL-IPI_Pat19	MEL-IPI_Pat19-Tumor-SM-4DK1F	
Biologically Relevant				Microsatellite Stability	Supporting variants		PRDM2 p.703_704insP (Insertion)																									0				Supporting variants: PRDM2 p.703_704insP (Insertion)		MEL-IPI_Pat19		
Biologically Relevant				Mutational Signature	COSMIC Signature 7	version 2	0.835																									0				COSMIC Signature (version 2) 7 (84%)		MEL-IPI_Pat19		
